Graviton Office Locations
Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases. TDI01, a highly selective, potent inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) is currently being studied in the United States for the treatment of idiopathic pulmonary fibrosis (IPF). Graviton anticipates entering human clinical studies in the U.S. in 2021.
graviton.bioGraviton Headquarters Location
245 Barclay Circle Suite 800, Rochester, MI 48307